Langton Hewer Simon C, Smyth Alan R
Paediatric Respiratory Medicine, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, Avon, UK, BS2 8BJ.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD004197. doi: 10.1002/14651858.CD004197.pub3.
Lower respiratory tract infection with Pseudomonas aeruginosa occurs in most people with cystic fibrosis (CF). Once chronic infection is established, Pseudomonas aeruginosa is virtually impossible to eradicate and is associated with increased mortality and morbidity. Early infection may be easier to eradicate.
To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with CF eradicates the organism, improves clinical and microbiological outcome and is superior to or more cost-effective than other strategies.
We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 11 December 2008.
We included randomised controlled trials (RCTs) of people with CF, in whom Pseudomonas aeruginosa had recently been isolated from respiratory secretions. We compared combinations of inhaled, oral or intravenous antibiotics with placebo, usual treatment or other combinations of inhaled, oral or intravenous antibiotics. We excluded non-randomised trials, cross-over trials, and those utilising historical controls.
Both authors independently selected trials, assessed methodological quality and extracted data.
The search identified 25 trials. Four trials (95 participants) were eligible for inclusion; two trials are ongoing. Evidence from two trials showed treatment of early Pseudomonas aeruginosa infection with inhaled tobramycin results in microbiological eradication of the organism from respiratory secretions more often than placebo, OR 0.15 (95% CI 0.03 to 0.65) and that this effect may persist for up to 12 months. These trials were of low methodological quality.The only identified RCT of oral ciprofloxacin and nebulised colistin versus usual treatment was of poor methodological quality. Results suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than usual treatment, after two years, OR 0.24 (95% CI 0.06 to 0.96). There is insufficient evidence to determine whether antibiotic strategies for the eradication of early Pseudomonas aeruginosa decrease mortality or morbidity, improve quality of life, or are associated with adverse effects compared to placebo or standard treatment.
AUTHORS' CONCLUSIONS: We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection with Pseudomonas aeruginosa. Eradication may be sustained in the short term. Overall, there is insufficient evidence from this review to state which antibiotic strategy should be used for the eradication of early Pseudomonas aeruginosa infection in CF.
大多数囊性纤维化(CF)患者会发生铜绿假单胞菌引起的下呼吸道感染。一旦形成慢性感染,铜绿假单胞菌实际上就无法根除,并且与死亡率和发病率的增加相关。早期感染可能更容易根除。
确定对患有CF的儿童和成人的早期铜绿假单胞菌感染进行抗生素治疗是否能根除该病原体,改善临床和微生物学结局,并且比其他策略更优或更具成本效益。
我们检索了Cochrane CF和遗传疾病小组试验注册库,该注册库包含通过全面电子数据库检索以及对相关期刊和会议论文摘要集进行手工检索所确定的参考文献。最近一次检索日期:2008年12月11日。
我们纳入了CF患者的随机对照试验(RCT),这些患者近期呼吸道分泌物中分离出了铜绿假单胞菌。我们比较了吸入、口服或静脉用抗生素的联合用药与安慰剂、常规治疗或其他吸入、口服或静脉用抗生素联合用药。我们排除了非随机试验、交叉试验以及使用历史对照的试验。
两位作者独立选择试验、评估方法学质量并提取数据。
检索到25项试验。4项试验(95名参与者)符合纳入标准;2项试验正在进行中。两项试验的证据表明,与安慰剂相比,用吸入性妥布霉素治疗早期铜绿假单胞菌感染更常使呼吸道分泌物中的该病原体在微生物学上被根除,比值比为0.15(95%可信区间0.03至0.65),并且这种效果可能持续长达12个月。这些试验的方法学质量较低。唯一一项确定的口服环丙沙星和雾化多粘菌素与常规治疗对比的RCT方法学质量较差。结果表明,两年后,与常规治疗相比,早期感染的治疗更常使铜绿假单胞菌在微生物学上被根除,比值比为0.24(95%可信区间0.06至0.96)。没有足够的证据来确定与安慰剂或标准治疗相比,根除早期铜绿假单胞菌的抗生素策略是否能降低死亡率或发病率、改善生活质量或是否会产生不良反应。
我们发现雾化抗生素单独或与口服抗生素联合使用,对于早期铜绿假单胞菌感染比不治疗要好。短期内根除效果可能持续。总体而言,本综述没有足够的证据说明应使用哪种抗生素策略来根除CF患者的早期铜绿假单胞菌感染。